Navigation Links
Neurobiological Technologies, Inc. Reports First Quarter Fiscal Year 2009 Financial Results
Date:11/6/2008

er=NTII" onClick="var s=s_gi(s_account); var hd1 = document.getElementById('headline'); s.tl(this,'o',getLinkName('Company Sanpshot'));" >NTII) is a biopharmaceutical company focused on developing novel, first-in-class agents for central nervous system conditions and other serious unmet medical needs. The Company's most advanced product candidate, Viprinex(TM) (ancrod), is in Phase 3 clinical testing as a novel investigational drug for the treatment of acute ischemic stroke. Viprinex has multiple mechanisms of action and is specifically designed to extend the time period that patients can be treated after the onset of a stroke. Acute ischemic stroke is one of the most prevalent, debilitating and costly diseases in the world for which there are few acceptable treatment options. NTI also has early-stage development programs for Alzheimer's and Huntington's diseases and rights to receive payments on an approved drug for Alzheimer's disease and an investigational drug in Phase 3 trials for brain swelling.

NOTE: Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including uncertainties regarding the development of Viprinex for acute ischemic stroke, delays or other problems with our clinical trials, the outcome of the interim analysis, the time and costs for obtaining approval for Viprinex, and levels of future expenditures and capital resources needed to fund operations, as well as other risks detailed from time to time in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K, as updated periodically in Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release and we undertake no obligation to update these forward-looking statements.


'/>"/>

SOURCE Neurobiological Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Neurobiological Technologies to Present at the Rodman & Renshaw 10th Annual Healthcare Conference in New York on November 10
2. Neurobiological Technologies Sets Date for First Quarter Financial Results
3. Neurobiological Technologies Reports Receipt of $2 Million Royalty Payment for Quarterly Sales of Memantine
4. Neurobiological Technologies to Present at the BIO Investor Forum in San Francisco on October 30, 2008
5. Neurobiological Technologies Announces Update Call on Viprinex (TM) Phase 3 Trial Program
6. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
7. Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit
8. Neurobiological Technologies Reports Receipt of $2.1 Million Royalty Payment for Quarterly Sales of Memantine
9. Neurobiological Technologies CEO to Retire on December 31, 2008
10. Neurobiological Technologies Reports Third Quarter Financial Results
11. Neurobiological Technologies Sets Date for Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... HAMILTON, Bermuda , July 1, 2015 /PRNewswire/ ... biopharmaceutical company focused on the treatment of dementia, ... investor briefing on July 22 at 5:45 p.m. ... at the Alzheimer,s Association International Conference 2015 (AAIC). ... following remarks: , Dr. Lawrence ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today that ... in Philadelphia, PA. , The presentation took place on Tuesday, June 16 ... for the development of APX3330 for the treatment of pancreatic cancer. A copy ...
(Date:6/30/2015)... , ... June 30, 2015 , ... ... 12 to take part in the first half of “Integrative Biotechnology,” an applied ... partnership established in summer 2014, this course combines students from both universities and ...
(Date:6/30/2015)...  Juniper Pharmaceuticals, Inc. (Nasdaq: JNP ), a ... address unmet medical needs in women,s health, today ... present at the Cantor Fitzgerald Inaugural Healthcare Conference ... 4:45 PM EDTLocation: , Le Parker Meridien Hotel, ... www.juniperpharma.com, under  ,Investor, or  click here ...
Breaking Biology Technology:Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 2Axovant Sciences To Host Investor Briefing And Live Webcast During AAIC 2015 Meeting 3Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Rivier University and Beijing City University Academic and Cultural Exchanges Begin 2Juniper Pharmaceuticals to Present at Cantor Fitzgerald Inaugural Healthcare Conference on July 8, 2015 2
... China, Feb. 6 /PRNewswire-Asia-FirstCall/ -- China Sky One ... (Nasdaq: CSKI ), a leading,fully integrated ... of China ("PRC"), today announced that the Company,s,Chief ... and conduct,one-on-one meetings at the upcoming Roth 21st ...
... 6 Tigris Pharmaceuticals, Inc., a privately held ... filed an Investigational New Drug (IND) application with ... GGTI-2418, a novel anticancer compound. GGTI-2418 is ... I) that appears to induce apoptosis by downregulating ...
... by $14 millionSEATTLE, Feb. 6 Cell Therapeutics, Inc. ... has engaged the services of a strategic advisory consulting ... developing strategic options for a partnership, asset divestment or ... the preclinical drug development arm of CTI, in Bresso, ...
Cached Biology Technology:China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Tigris Pharmaceuticals Files IND Application for GGTI-2418 2Tigris Pharmaceuticals Files IND Application for GGTI-2418 3CTI Seeks Strategic Alternative for Italian Facility 2CTI Seeks Strategic Alternative for Italian Facility 3
(Date:6/17/2015)... Germany , June 17, 2015 ... today launched new Investigator ® STR assay kits for ... the United States . The new genetic fingerprint kits ... markers (short tandem repeats or STRs) for DNA matching. They ... quality of DNA in each sample, a novel QIAGEN technology ...
(Date:6/16/2015)... June 16, 2015 /CNW Telbec/ - handyem Inc. ... around the incorporation of handyem,s HPC-150 portable flow ... the Mo-POD™. This unprecedented model of mobile laboratory ... at the Pennsylvania Convention ... 15 th to 18 th 2015. ...
(Date:6/16/2015)... 2015 Fingerprint Cards (FPC) raises the ... will amount to at least 340 MSEK to that it ... increase in market growth and orders received the revenue guidance ... revenue for 2015 will exceed 1,500 MSEK to an updated ... MSEK. Due to receipt of orders of touch ...
Breaking Biology News(10 mins):QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 2Fingerprint Cards Raises the Revenue Guidance for Q2 2015 and for the Full Year 2015 3
... a new imaging system that allows them to see ... work, which could help scientists understand how precancerous mutations ... to pinpoint the number and location of mutant cellscells ... the researchers worked with mouse pancreatic cells. "Understanding ...
... When individuals infected with HIV become infected with a ... can exchange genetic information, creating a third, recombinant strain ... presence of multiple viral strains, called superinfection, frequently leads ... Now a study from the Partners AIDS Research ...
... from four leading cancer centers have confirmed that an analysis ... which lung cancer patients will have the worst survival. The ... help determine who needs more aggressive treatment. The study, ... Medicine . The researchers looked at 442 lung ...
Cached Biology News:MIT researchers offer glimpse of rare mutant cells 2Viral recombination another way HIV fools the immune system 2Gene panel predicts lung cancer survival, study finds 2
... Mass Standards Kit includes reagents that can ... instrument parameters, and calibrate the mass scale ... designed for use with the 4700 Proteomics ... Standards in the kit require minimal preparation ...
...
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
Biology Products: